• Lundbeck H1 2026 revenue rose 11% to DKK 13.59 billion, driven by double-digit growth in the U.S. and Europe.
• EBITDA increased 11% to DKK 4.61 billion; EPS climbed 36% to DKK 2.83.
• Strategic-brand revenue grew 11% to DKK 10.46 billion, led by Vyepti up 36% to DKK 2.87 billion.
• Rexulti advanced 8% to DKK 3.3 billion; Brintellix/Trintellix slipped 2% to DKK 2.33 billion.
• CEO Charl van Zyl cited strong commercial momentum for Vyepti; enrollment completed in the DEEp OCEAN phase III bexicaserin trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202608190100BITN____UKPR__EN_20260819-BIT-9291-0) on August 19, 2026, and is solely responsible for the information contained therein.